In the recent Commissioner's Decision Re Amgen Research
(Munich) GmbH (2021 CACP 2), the Patent Appeal Board
allowed medical use claims reciting a dosage range in Amgen's
Canadian Patent Application 2,633,594 (the 594 application).
It is well known that in Canada, while methods of medical
treatment are not patentable subject matter, medical use claims are
considered patentable. Nevertheless, there have been several
Federal Court decisions1 where a claim directed to the
exercise of professional skill or judgment, for instance a claim
containing a dosage range, was held to be not patentable.2 Consequently, CIPO issued the 2015 Revised Examination Practice Notice
(PN 2015-01), which specified that where an essential
element of a medical use claim prevents, interferes with or
requires the professional skill of a physician, the claim is
considered to encompass a method of medical treatment and is not
patentable subject matter under s.2 of the Patent Act.